ATYR Earnings

ATYR reported its earnings on 2025-11-06, showcasing a revenue of 190.00K against an estimate of 27.00M, resulting in a -99.3% surprise. The EPS was -0.26, surpassing the expected -0.2 by -30% . The stock experienced a 6.05% price change on the earnings day and a -6.17% change over the next five days, reflecting market reactions to the results.

Following ATYR's earnings announcement on 2025-11-06, the stock price moved by 6.05% on the day of the release. Over the subsequent five days, it saw a -6.17% change. Historically, ATYR's stock price tends to shift by an average of +5.01% in the 10 days leading up to earnings and -4.47% in the 10 days following, providing insight into potential market.

For , analysts estimate ATYR’s annual revenue to reach , while the EPS is projected at . These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -89.53% and EPS estimates No Change by 0% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between ATYR's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -89.53%, while EPS estimates moved No Change by 0% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ATYR's stock price typically moves by +5.01% in the 10 days before its earnings and -4.47% in the 10 days after. For the upcoming earnings, analysts expect an EPS of and revenue of .

The earnings call reveals a mixed sentiment. Positive factors include the significant milestone payments from the Kyorin agreement and a healthy cash position. However, the ATM offering may dilute share value, and the Q&A section highlights some uncertainties, such as lack of clarity on patient data and FDA interactions. The increase in R&D expenses suggests ongoing investment but may impact short-term profitability. Overall, these mixed signals suggest a neutral market reaction, with no clear catalyst for a significant stock price movement.